Using the FACE-Q—a validated, patient-reported outcome instrument—to assess patient satisfaction following botulinum toxin type A injections, Brian L. Chang, MD, et al, sought to quantify patient satisfaction following treatment with each of three currently available neurotoxins.
The study, published in the Aesthetic Surgery Journal (July 2016), followed 57 female patients who received injections of one of onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) or incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) in the glabella. Subjects completed the FACE-Q survey, used to evaluate patient satisfaction with their facial appearance, at baseline and two weeks post-injection.
Patient satisfaction with overall facial appearance increased by 28% following neuromodulation with subjects reporting that they believe they look an average of 5.6 years younger post-injection. There were no significant differences in satisfaction among the three treatment groups.
